遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクターの世界市場レポート 2025年

遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.6%で60億9,000万米ドルに成長します。予測期間中に予想される成長は、AAVカプシド工学の継続的な進歩、精密医療への重点の高まり、遺伝子研究とバイオテクノロジーへの投資の増加、遺伝子治療の臨床検査と規制承認の急増、個別化治療アプローチへの需要の高まりに起因しています。この期間に予想される主要動向には、AAVキャプシド設計における人工知能の統合、より大きな遺伝子ペイロードを運ぶことができるハイブリッドAAVベクターの開発、二重特異性抗体を介したAAVターゲティングの革新、スケーラブルなAAV製造と精製方法の進歩、さまざまなウイルスベクターアプリケーションをサポートする適応可能なAAVプラットフォームの構築などがあります。

遺伝子ベースの治療が重視されるようになったことで、遺伝子治療市場におけるアデノ随伴ウイルス（AAV）ベクターの成長が促進されると予想されます。遺伝子による治療には、分子レベルでの病気の予防、治療、治癒を目的とした遺伝子の改変や操作が含まれます。遺伝子研究の開発は、遺伝子編集技術の精度と有効性を向上させることで、これらの治療法の開発に拍車をかけています。AAVベクターは、その低い免疫原性と長期間の遺伝子発現能力により、治療用遺伝子を標的細胞に安全かつ効率的に送達することで、遺伝子治療において重要な役割を果たしています。例えば、ライフサイエンス産業向けに分析技術ソリューションを提供する米国IQVIAは2023年、細胞・遺伝子治療に対する世界の支出が59億米ドルに達し、2022年比で38％増加したと報告しています。その結果、遺伝子による治療への注目の高まりがAAVベクター市場の拡大に寄与しています。

遺伝子治療市場のAAVベクター部門に関与する企業は、アッセイの多様性を高めるためのベクター多様性の導入など、技術革新に注力しています。この戦略は、組織特異性や治療効果を高め、さまざまな症状に対してカスタマイズ型遺伝子治療の開発をサポートします。ベクターの多様性とは、さまざまなAAV血清型やコンストラクトを使用し、さまざまな分析手順や治療応用をサポートすることです。例えば、2024年5月、米国の製薬会社チャールズ・リバー・ラボラトリーズは、アデノ随伴ウイルス（AAV）とレンチウイルスベクター（LVV）の新しい標準物質を発売しました。これらの標準物質は、細胞・遺伝子治療（CGT）開発における需要の高まりに対応するよう設計されており、初期研究からGMPグレードの製造への移行を容易にします。今回の上市は、製造プロセスを標準化し、ウイルスベクター製造の一貫性を向上させることを目的としており、CGTプログラムを臨床・商業段階へと進める上での大きな課題に対処するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクターPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場：成長率分析
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場の実績：規模と成長、2019～2024年
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場の予測：規模と成長、2024～2029年、2034年
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 遺伝子増強
• 免疫療法
• その他タイプの治療法
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場：使用遺伝子送達方法タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• Ex Vivo
• In Vivo
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場：事業規模別、実績と予測、2019～2024年、2024～2029年、2034年
• 前臨床
• 臨床
• 手術
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場、対象治療領域別、実績と予測、2019～2024年、2024～2029年、2034年
• 遺伝性疾患
• 血液疾患
• 感染症
• 代謝障害
• 眼疾患
• 筋肉障害
• 神経疾患
• その他の対象治療領域
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場、遺伝子増強のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 単一遺伝子疾患
• 神経疾患
• 筋肉疾患
• 眼科疾患
• 代謝障害
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場、免疫療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 腫瘍学
• 感染症
• 自己免疫疾患
• ワクチン開発
• T細胞工学
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場、その他タイプの治療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 遺伝子編集サポート
• RNA干渉
• 神経保護と神経再生
• 抗炎症用途
• 再生医療

第7章 地域別・国別分析

• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場：競合情勢
• 遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • Sanofi S.A.
  • Novartis AG
  • Astellas Gene Therapies Inc.
  • Biogen Inc.

第31章 その他の大手企業と革新的企業

• Sarepta Therapeutics Inc.
• Oxford BioMedica plc
• Rocket Pharmaceuticals Inc.
• Aldevron LLC
• REGENXBIO Inc.
• uniQure N.V.
• Passage Bio Inc.
• Voyager Therapeutics Inc.
• Dyno Therapeutics Inc.
• MeiraGTx Holdings plc
• Abeona Therapeutics Inc.
• 4D Molecular Therapeutics Inc.
• GenSight Biologics S.A.
• Taysha Gene Therapies Inc.
• LogicBio Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場、2029年：新たな機会を提供する国
• 遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場、2029年：新たな機会を提供するセグメント
• 遺伝子治療におけるアデノ随伴ウイルス（AVV）ベクター市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Adeno-associated virus (AAV) vectors are advanced gene therapy delivery systems designed to transport genetic material into cells for the treatment of various genetic conditions. Their main objective is to provide targeted and long-lasting therapeutic outcomes by repairing or modifying defective genes. AAV vectors are highly regarded for their safety profile, minimal immune response, and ability to deliver genes to both dividing and non-dividing cells, thereby supporting the creation of precise and lasting gene therapies that enhance personalized medicine and revolutionize the management of rare and inherited diseases.

The primary categories of adeno-associated virus (AAV) vectors include gene augmentation, immunotherapy, and other therapeutic approaches. Gene augmentation involves introducing a functional gene into a cell to replace or supplement a missing or defective one. This can be achieved through various delivery techniques, such as ex vivo and in vivo methods. These therapies are developed and applied at multiple operational stages, including preclinical, clinical, and commercial levels. The targeted therapeutic areas encompass genetic disorders, blood-related diseases, infectious illnesses, metabolic conditions, eye disorders, muscular diseases, and neurological disorders.

The adeno-associated virus (AVV) vectors in gene therapy market research report is one of a series of new reports from The Business Research Company that provides adeno-associated virus (AVV) vectors in gene therapy market statistics, including precision weight industry global market size, regional shares, competitors with an adeno-associated virus (AVV) vectors in gene therapy market share, precision weight market segments, market trends, and opportunities, and any further data you may need to thrive in the adeno-associated virus (AVV) vectors in gene therapy industry. This adeno-associated virus (AVV) vectors in gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adeno-associated virus (AVV) vectors in gene therapy market size has grown rapidly in recent years. It will grow from $2.70 billion in 2024 to $3.18 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth during the historic period can be credited to greater investment in gene therapy research, the growing use of gene editing technologies, an increase in genetic disorders and unmet medical needs, rising demand for targeted treatments, and enhanced collaboration between biotechnology companies and research organizations.

The adeno-associated virus (AVV) vectors in gene therapy market size is expected to see rapid growth in the next few years. It will grow to $6.09 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The anticipated growth in the forecast period can be attributed to ongoing advancements in AAV capsid engineering, a heightened emphasis on precision medicine, increasing investments in genetic research and biotechnology, a surge in gene therapy clinical trials and regulatory approvals, and a growing demand for personalized treatment approaches. Key trends expected during this period include the integration of artificial intelligence in AAV capsid design, the development of hybrid AAV vectors capable of carrying larger genetic payloads, innovations in bispecific antibody-mediated AAV targeting, progress in scalable AAV manufacturing and purification methods, and the creation of adaptable AAV platforms that support a variety of viral vector applications.

The rising emphasis on gene-based therapies is expected to drive the growth of the adeno-associated virus (AAV) vectors in the gene therapy market. Gene-based therapies involve the modification or manipulation of genes to prevent, treat, or cure diseases at the molecular level. Advances in genetic research are fueling the development of these therapies by improving the precision and effectiveness of gene editing techniques. AAV vectors play a key role in gene therapy by safely and efficiently delivering therapeutic genes into target cells, thanks to their low immunogenicity and capacity for long-term gene expression. For example, in 2023, IQVIA, a U.S.-based provider of analytics and technology solutions for the life sciences industry, reported that global spending on cell and gene therapies reached $5.9 billion, a 38% increase compared to 2022. As a result, the growing focus on gene-based therapies is contributing to the expansion of the AAV vectors market.

Companies involved in the AAV vectors segment of the gene therapy market are concentrating on technological innovation, such as introducing tailored vector diversity for assay versatility. This strategy enhances tissue specificity, therapeutic effectiveness, and supports the development of customized gene therapies for a range of conditions. Tailored vector diversity refers to the use of various AAV serotypes or constructs to support different analytical procedures and therapeutic applications. For instance, in May 2024, Charles River Laboratories, a U.S.-based pharmaceutical company, launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are designed to meet the growing demands of cell and gene therapy (CGT) development, facilitating the transition from early research to GMP-grade manufacturing. The launch aims to standardize production processes and improve consistency in viral vector manufacturing, addressing a major challenge in advancing CGT programs toward clinical and commercial stages.

In March 2023, Ginkgo Bioworks, a U.S.-based biotechnology company, acquired assets related to StrideBio's AAV capsid discovery and engineering platform for an undisclosed amount. This acquisition is intended to strengthen Ginkgo Bioworks' research and development capabilities in gene therapy, with a focus on creating novel adeno-associated virus (AAV) capsids to enhance gene delivery. StrideBio is a U.S.-based biotech company specializing in the development of engineered AAV capsids for use in gene therapy applications.

Major players in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in adeno-associated virus (AAV) vectors in gene therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adeno-associated virus (AAV) vectors in gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adeno-associated virus (AAV) vectors in gene therapy market consists of revenues earned by entities by providing services such as gene delivery solutions, targeted therapeutic development, long-term gene expression, and treatment of genetic disorders through safe and efficient viral vector technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The adeno-associated virus (AAV) vectors in gene therapy market includes sales of viral vector delivery systems used for transporting genetic material into patient cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adeno-associated virus (avv) vectors in gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adeno-associated virus (avv) vectors in gene therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adeno-associated virus (avv) vectors in gene therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type of Therapy: Gene Augmentation; Immunotherapy; Other Type of Therapy
• 2) By Type of Gene Delivery Method Used: Ex Vivo; In Vivo
• 3) By Scale of Operation: Preclinical; Clinical; Commercial
• 4) By Target Therapeutic Area: Genetic Disorders; Hematological Disorders; Infectious Diseases; Metabolic Disorders; Ophthalmic Disorders; Muscle Disorders; Neurological Disorders; Other Target Therapeutic Area
• Subsegments:
• 1) By Gene Augmentation: Monogenic Disorders; Neurological Disorders; Muscular Disorders; Ophthalmological Disorders; Metabolic Disorders
• 2) By Immunotherapy: Oncology; Infectious Diseases; Autoimmune Disorders; Vaccine Development; T-Cell Engineering
• 3) By Other Type of Therapy: Gene Editing Support; RNA Interference; Neuroprotection and Neuroregeneration; Anti-Inflammatory Applications; Regenerative Medicine
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Sanofi S.A.; Novartis AG; Astellas Gene Therapies Inc.; Biogen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Characteristics

3. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Trends And Strategies

4. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth Rate Analysis
• 5.4. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Total Addressable Market (TAM)

6. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segmentation

• 6.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Augmentation
• Immunotherapy
• Other Type Of Therapy
• 6.2. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ex Vivo
• In Vivo
• 6.3. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preclinical
• Clinical
• Commercial
• 6.4. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Disorders
• Hematological Disorders
• Infectious Diseases
• Metabolic Disorders
• Ophthalmic Disorders
• Muscle Disorders
• Neurological Disorders
• Other Target Therapeutic Area
• 6.5. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Gene Augmentation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monogenic Disorders
• Neurological Disorders
• Muscular Disorders
• Ophthalmological Disorders
• Metabolic Disorders
• 6.6. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Infectious Diseases
• Autoimmune Disorders
• Vaccine Development
• T-Cell Engineering
• 6.7. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Other Type of Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Editing Support
• RNA Interference
• Neuroprotection and Neuroregeneration
• Anti-Inflammatory Applications
• Regenerative Medicine

7. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Regional And Country Analysis

• 7.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 8.1. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 9.1. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 9.2. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 10.1. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 11.1. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 11.2. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 12.1. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 13.1. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 14.1. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 14.2. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 15.1. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 15.2. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 16.1. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 17.1. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 18.1. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 19.1. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 20.1. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 21.1. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 21.2. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 22.1. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 23.1. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 23.2. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 24.1. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 24.2. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 25.1. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 25.2. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 26.1. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 26.2. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 27.1. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 28.1. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 28.2. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

• 29.1. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
• 29.2. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape And Company Profiles

• 30.1. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape
• 30.2. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Astellas Gene Therapies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Other Major And Innovative Companies

• 31.1. Sarepta Therapeutics Inc.
• 31.2. Oxford BioMedica plc
• 31.3. Rocket Pharmaceuticals Inc.
• 31.4. Aldevron LLC
• 31.5. REGENXBIO Inc.
• 31.6. uniQure N.V.
• 31.7. Passage Bio Inc.
• 31.8. Voyager Therapeutics Inc.
• 31.9. Dyno Therapeutics Inc.
• 31.10. MeiraGTx Holdings plc
• 31.11. Abeona Therapeutics Inc.
• 31.12. 4D Molecular Therapeutics Inc.
• 31.13. GenSight Biologics S.A.
• 31.14. Taysha Gene Therapies Inc.
• 31.15. LogicBio Therapeutics Inc.

32. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

34. Recent Developments In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

35. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market High Potential Countries, Segments and Strategies

• 35.1 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer